A promising therapeutic vaccine, L-BLP25, commercially also known as tecemotide, has been developed as an immunotherapy for NSCLC, specifically targeting MUC1 to enhance treatment efficacy [32]. The gene discussed is MUC1; the disease is non-small cell lung carcinoma.